NCT06998056 - Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Atopic Dermatitis (Eczema)

Interventions

DRUG

ARQ-151 cream 0.05%

ARQ-151 Cream 0.05% is applied once daily for 4 weeks in infants with atopic dermatitis (eczema).

Trial Locations (13)

32256

RECRUITING

Arcutis Clinical Study Site 213, Jacksonville

33146

RECRUITING

Arcutis Clinical Study Site 207, Coral Gables

35244

RECRUITING

Arcutis Clinical Study Site 208, Birmingham

45040

RECRUITING

Arcutis Clinical Study Site 220, Mason

47906

RECRUITING

Arcutis Clinical Study Site 219, West Lafayette

55112

RECRUITING

Arcutis Clinical Study Site 212, Minneapolis

72022

RECRUITING

Arcutis Clinical Study Site 221, Bryant

76244

RECRUITING

Arcutis Clinical Study Site 224, Fort Worth

92688

RECRUITING

Arcutis Clinical Study Site 209, Rancho Santa Margarita

03801

RECRUITING

Arcutis Clinical Study Site 211, Portsmouth

R3J0S9

RECRUITING

Arcutis Clinical Study Site 203, Winnipeg

N2J1C4

RECRUITING

Arcutis Clinical Study Site 216, Waterloo

S7K2C1

RECRUITING

Arcutis Clinical Study Site 225, Saskatoon